A comprehensive review of adherence to diabetes and cardiovascular medications in Iran; implications for practice and research

Journal of Diabetes and Metabolic Disorders

Volumn 12, Issue 1, 2013, Pages

  Sarayani, Amir ^a   Jahangard Rafsanjani, Zahra ^b   Hadjibabaie, Molouk ^a,b   Ahmadvand, Alireza ^c   Javadi, Mohammadreza ^b   Gholami, Kheirollah ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Hypertension; Iran; Medication adherence; Oral hypoglycemic medications; Patient compliance; Patient education

Indexed keywords

CARDIOVASCULAR AGENT; INSULIN; ORAL ANTIDIABETIC AGENT;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INSULIN TREATMENT; IRAN; IRANIAN PEOPLE; MEDICATION ADHERENCE RATING SCALE; MEDICATION COMPLIANCE; MORISKY MEDICATION ADHERENCE SCALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; QUESTIONNAIRE; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TELEMEDICINE;

EID: 84908053541     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-12-57     Document Type: Review

References (48)

1. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47. 10.1111/j.1524-4733.2007.00213.x, 18237359.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497. 10.1056/NEJMra050100, 16079372.
3. Brown MT, Bussell JK. Medication adherence: WHO Cares?. Mayo Clin Proc 2011, 86:304-314. 10.4065/mcp.2010.0575, 3068890, 21389250.
4. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006, 43:939-941. 10.1086/507526, 16941380.
5. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother 2011, 45:372-379. 10.1345/aph.1P587, 21386024.
6. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177-186. 10.1001/jama.297.2.177, 17213401.
7. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006, 333:15. 10.1136/bmj.38875.675486.55, 1488752, 16790458.
8. Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009, 12:915-922. 10.1111/j.1524-4733.2009.00539.x, 19402848.
9. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224. 10.2337/diacare.27.5.1218, 15111553.
10. Baroletti S, Dell'Orfano H. Medication adherence in cardiovascular disease. Circulation 2010, 121:1455-1458. 10.1161/CIRCULATIONAHA.109.904003, 20351303.
11. Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J 2009, 15:591-599.
12. Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Khamseh ME, Kharazmi E, Sadeghi A. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One 2011, 6:e26864. 10.1371/journal.pone.0026864, 3204988, 22066013.
13. Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S, Mahdavi Hezaveh N, Kazemeini H. The burden of disease and injury in Iran 2003. Popul Health Metr 2009, 7:9. 10.1186/1478-7954-7-9, 2711041, 19527516.
14. Sadeghi M, Roohafza HR, Kelishadi R. Blood pressure and associated cardiovascular risk factors in Iran: Isfahan Healthy Heart Programme. Med J Malaysia 2004, 59:460-467.
15. Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Adherence to glyburide and metformin and associated factors in type 2 diabetes in Isfahan, Iran. Iran J Pharm Res 2011, 10:933-939. 3813068, 24250432.
16. Hadi N, Rostami-Gooran N. Determinant factors of medication compliance in hypertensive patients of Shiraz, Iran. Arch Iran Med 2004, 7:292-296.
17. Gellad WF, Grenard J, McGlynn EA. A Review of Barriers to Medication Adherence: A Framework for Driving Policy Options 2009, Santa Monica, CA: RAND Corporation, http://www.rand.org/pubs/technical_reports/TR765.
18. Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007, 44:1468-1477. 10.1016/j.ijnurstu.2006.07.010, 16973166.
19. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005, 22:313-356. 10.1007/BF02850081, 16418141.
20. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, Issue 2. Art. No.: CD000011. DOI: 10.1002/14651858.CD000011.pub3.
21. Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK. A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med 2011, 26:1479-1491. 10.1007/s11606-011-1825-3, 3235604, 21858602.
22. Cheraghali AM, Nikfar S, Behmanesh Y, Rahimi V, Habibipour F, Tirdad R, Asadi A, Bahrami A. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. East Mediterr Health J 2004, 10:406-415.
23. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297. 10.1371/journal.pmed.0040297, 2020496, 17941715.
24. Critical Appraisal Skills Programme(CASP) Checklist; making sense of evidence. Solut Public Health, NHS http://www.casp-uk.net/find-appraise-act/appraising-the-evidence/.
25. Parsa-Yekta Z, Moghaddam Z, Mehran A, Palizdar M. Study of medication compliance of patients with coronary heart diseases and associated factors [Farsi]. HAYAT 2004, 9:34-44.
26. Dabaghian H, Karbakhsh-davari M, Soheilikhah S, Sedaghat M. [Adherence to medications in type 2 diabetic patients in Shariati and imam Khomeini hospitals] (Fa). Payesh 2005, 4:111-103.
27. Zolfaghari M, Mousavifar SA, Pedram S, Haghani H. The impact of nurse short message services and telephone follow-ups on diabetic adherence: which one is more effective?. J Clin Nurs 2012, 21:1922-1931. 10.1111/j.1365-2702.2011.03951.x, 22239205.
28. Nesari M, Zakerimoghadam M, Rajab A, Bassampour S, Faghihzadeh S. Effect of telephone follow-up on adherence to a diabetes therapeutic regimen. Jpn J Nurs Sci 2010, 7:121-128. 10.1111/j.1742-7924.2010.00146.x, 21092015.
29. Heydari A, Ahrari S, Vaghee S. The relationship between self-concept and adherence to therapeutic regimens in patients with heart failure. J Cardiovasc Nurs 2011, 26:475-480. 10.1097/JCN.0b013e318215bb78, 21558864.
30. Hadi N, Rostami-Gooran N. Effectiveness of a hypertension educational program on increasing medication compliance in Shiraz, 2004. Shiraz E Medical J 2006, 7:1-6.
31. Aflakseir A. The role of illness and medication perceptions on adherence to medicines in a group of Iranian patients with type 2 diabetes. J Diabetes 2012, 4:243-247. doi: 10.1111/j.1753-0407.2012.00183.x, 10.1111/j.1753-0407.2012.00183.x, 22221835.
32. Abbasi M, Salemi S, Fatemi NS, Hosseini F. Hypertensive patients, their compliance level and its relation to their health beliefs. Iran J Nurs 2005, 18:61-68.
33. Alizad-jahani S, Majdzadeh R, Ghorbani M, Khosravi S, Bajoori A, Larijani M. [Evaluation of factors underlying non-adherence to insulin therapy in Iranian diabetic patients 2010-2011; a qualitative study] (Fa). Majalleh Diabet va Lipid Iran 2011, 10:520-527.
34. Mohammadi E, Abedi HA, Gofranipour F, Jalali F. Partnership caring: a theory of high blood pressure control in Iranian hypertensives. Int J Nurs Pract 2002, 8:324-329. 10.1046/j.1440-172X.2002.00386.x, 12390585.
35. Heydari A, Ziaee ES, Ebrahimzadeh S. The frequency of rehospitalization and its contributing factors in patients with cardiovascular diseases hospitalized in selected hospitals in Mashhad in 2010. Ofogh-e-Danesh; J Gonabad Univ Med Sci 2011, 17:65-71.
36. Mohamadi M, Dadkhah B, Sezavar S-H, Mozafari N. Impact of follow-up program on control of high blood pressure in hypertensive patients. J Ardabil Univ Med Sci 2006, 6:156-162.
37. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002, 40:794-811. 10.1097/00005650-200209000-00009, 12218770.
38. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155:772-779. 10.1016/j.ahj.2007.12.011, 18371492.
39. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006, 166:1836-1841. 10.1001/archinte.166.17.1836, 17000939.
40. Yang Y, Thumula V, Pace PF, Banahan BF, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009, 31:2178-2188. discussion 2150-2171, 10.1016/j.clinthera.2009.10.002, 19922889.
41. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 2011, 9:11-23. 10.1016/j.amjopharm.2011.02.004, 3084587, 21459305.
42. Andrade AS, McGruder HF, Wu AW, Celano SA, Skolasky RL, Selnes OA, Huang IC, McArthur JC. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis 2005, 41:875-882. 10.1086/432877, 16107989.
43. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005, 6:185-190. 10.1111/j.1468-1293.2005.00287.x, 15876285.
44. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010, Issue 3. Art. No.: CD004371. DOI: 10.1002/14651858.CD004371.pub3.
45. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004, Issue 3. Art. No.: CD004804. DOI: 10.1002/14651858.CD004804.
46. Gwadry-Sridhar FH, Manias E, Zhang Y, Roy A, Yu-Isenberg K, Hughes DA, Nichol MB. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 2009, 31:421-435. 10.1016/j.clinthera.2009.02.021, 19302915.
47. Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS. Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol 2011, 64:250-254. 10.1016/j.jclinepi.2010.07.014, 3634915, 21194887.
48. Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol 2011, 11:149. 10.1186/1471-2288-11-149, 3219622, 22050830.